HC Wainwright Boosts Xeris Biopharma (NASDAQ:XERS) Price Target to $6.60

Xeris Biopharma (NASDAQ:XERS) had its price target lifted by HC Wainwright from $6.00 to $6.60 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Monday.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $3.28 on Monday. The firm has a market capitalization of $488.72 million, a price-to-earnings ratio of -7.29 and a beta of 2.70. Xeris Biopharma has a 52-week low of $1.46 and a 52-week high of $3.64. The stock has a fifty day moving average of $2.97 and a 200 day moving average of $2.51.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of XERS. Intech Investment Management LLC purchased a new position in Xeris Biopharma during the 3rd quarter valued at about $130,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Xeris Biopharma during the 3rd quarter valued at about $237,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after acquiring an additional 11,239 shares during the period. Goldstein Advisors LLC grew its holdings in shares of Xeris Biopharma by 19.7% during the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after acquiring an additional 5,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of Xeris Biopharma during the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.